Northern Trust’s Lipocine LPCN Stock Holding History

Northern Trust’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$104K	Sell	13,042 -118	-0.9%	-$1.03K	﹤0.01%	4095
2025 Q4	$106K	Hold	13,160	–	–	﹤0.01%	4130
2025 Q3	$37.5K	Hold	13,160	–	–	﹤0.01%	4319
2025 Q2	$41.6K	Hold	13,160	–	–	﹤0.01%	4262
2025 Q1	$41.8K	Hold	13,160	–	–	﹤0.01%	4251
2024 Q4	$64.2K	Hold	13,160	–	–	﹤0.01%	4229
2024 Q3	$59.1K	Hold	13,160	–	–	﹤0.01%	4173
2024 Q2	$108K	Buy	+13,160	New	+$82.3K	﹤0.01%	4034
2023 Q2	–	Sell	-9,447	Closed	-$51.1K	–	4568
2023 Q1	$51.1K	Hold	9,447	–	–	﹤0.01%	4266
2022 Q4	$63.9K	Hold	9,447	–	–	﹤0.01%	4221
2022 Q3	$72K	Hold	9,447	–	–	﹤0.01%	4220
2022 Q2	$129K	Sell	9,447 -449	-5%	-$7K	﹤0.01%	4078
2022 Q1	$230K	Hold	9,896	–	–	﹤0.01%	4071
2021 Q4	$167K	Sell	9,896 -20	-0.2%	-$371	﹤0.01%	4258
2021 Q3	$184K	Sell	9,916 -267	-3%	-$5.89K	﹤0.01%	4214
2021 Q2	$242K	Buy	10,183 +1,464	+17%	+$34.4K	﹤0.01%	4071
2021 Q1	$224K	Buy	8,719 +1,413	+19%	+$40.8K	﹤0.01%	4074
2020 Q4	$169K	Buy	7,306 +2,101	+40%	+$50.6K	﹤0.01%	4015
2020 Q3	$125K	Buy	5,205 +1,837	+55%	+$48.8K	﹤0.01%	3915
2020 Q2	$72K	Buy	3,368 +443	+15%	+$5.74K	﹤0.01%	3983
2020 Q1	$24K	Hold	2,925	–	–	﹤0.01%	4066
2019 Q4	$19K	Sell	2,925 -17	-0.6%	-$435	﹤0.01%	4164
2019 Q3	$141K	Sell	2,942 -47	-2%	-$1.89K	﹤0.01%	3846
2019 Q2	$99K	Hold	2,989	–	–	﹤0.01%	3973
2019 Q1	$117K	Hold	2,989	–	–	﹤0.01%	3892
2018 Q4	$66K	Sell	2,989 -12	-0.4%	-$278	﹤0.01%	3998
2018 Q3	$70K	Hold	3,001	–	–	﹤0.01%	4083
2018 Q2	$66K	Buy	3,001 +447	+18%	+$10.7K	﹤0.01%	4080
2018 Q1	$66K	Hold	2,554	–	–	﹤0.01%	4045
2017 Q4	$149K	Buy	2,554 +69	+3%	+$4.29K	﹤0.01%	3894
2017 Q3	$167K	Buy	2,485 +678	+38%	+$49K	﹤0.01%	3841
2017 Q2	$123K	Sell	1,807 -8,570	-83%	-$559K	﹤0.01%	3925
2017 Q1	$688K	Sell	10,377 -317	-3%	-$20.5K	﹤0.01%	3456
2016 Q4	$669K	Sell	10,694 -54	-0.5%	-$3.42K	﹤0.01%	3460
2016 Q3	$815K	Sell	10,748 -58	-0.5%	-$3.59K	﹤0.01%	3402
2016 Q2	$559K	Buy	10,806 +8,457	+360%	+$1.31M	﹤0.01%	3489
2016 Q1	$406K	Sell	2,349 -411	-15%	-$70.1K	﹤0.01%	3515
2015 Q4	$607K	Buy	2,760 +882	+47%	+$185K	﹤0.01%	3460
2015 Q3	$377K	Buy	1,878 +776	+70%	+$180K	﹤0.01%	3559
2015 Q2	$161K	Buy	+1,102	New	+$137K	﹤0.01%	3832

Other funds holding LPCN

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $318M AUM

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Northern Trust's LPCN Position: Q1 2026 in Review

Northern Trust reduced its Lipocine (LPCN) stake by 0.9% in Q1 2026, selling an estimated $1.03K and leaving 13,042 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4095.

Northern Trust first reported a position in LPCN in Q2 2015 and has held it in 40 quarters since. The position peaked at $815K in Q3 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

Northern Trust held 13,042 shares of Lipocine worth $104K as of Q1 2026.
Northern Trust sold 118 Lipocine shares in Q1 2026, an estimated $1.03K.
Lipocine made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4095 holding.
Northern Trust first reported a position in Lipocine in Q2 2015 and has held it in 40 quarters since.
Northern Trust's Lipocine position peaked at $815K in Q3 2016.
47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.